Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/24518Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kiortsis, D. N. | en |
| dc.contributor.author | Filippatos, T. D. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.date.accessioned | 2015-11-24T19:41:40Z | - |
| dc.date.available | 2015-11-24T19:41:40Z | - |
| dc.identifier.issn | 1262-3636 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/24518 | - |
| dc.rights | Default Licence | - |
| dc.subject | orlistat | en |
| dc.subject | weight loss | en |
| dc.subject | cholesterol | en |
| dc.subject | metabolic parameters | en |
| dc.subject | insulin | en |
| dc.subject | diabetes | en |
| dc.subject | coronary-heart-disease | en |
| dc.subject | randomized controlled-trial | en |
| dc.subject | placebo-controlled trial | en |
| dc.subject | obese-patients | en |
| dc.subject | weight-loss | en |
| dc.subject | lipase inhibitor | en |
| dc.subject | serum-lipids | en |
| dc.subject | double-blind | en |
| dc.subject | body-weight | en |
| dc.subject | postprandial lipemia | en |
| dc.title | The effects of orlistat on metabolic parameters and other cardiovascular risk factors | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | <Go to ISI>://000227426300002 | - |
| heal.identifier.secondary | http://ac.els-cdn.com/S1262363607701611/1-s2.0-S1262363607701611-main.pdf?_tid=7941c0c88034fcd656dd9979e1d8130c&acdnat=1332756673_3043d3864000e468732cf0601204b908 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2005 | - |
| heal.abstract | Orlistat is an antiobesity drug with a well documented efficacy in weight reduction and weight maintenance. Weight reduction with orlistat has been associated with a favourable effect on obesity-related cardiovascular risk factors. Orlistat treatment is associated with a reduction in serum insulin levels. Moreover, orlistat reduces the incidence of type 2 diabetes in patients with impaired glucose tolerance and lowers the required dose of metformin, sulfonylureas and insulin in patients with type 2 diabetes. Furthermore, orlistat can reduce total and low density lipoprotein (LDL) cholesterol levels and improve postprandial triglyceridemia, as well as the low density lipoprotein cholesterol / high density lipoprotein cholesterol ratio (LDL/HDL ratio). Moreover, orlistat appears to have a favourable effect on some inflammatory markers, such as TNF-alpha and interleukin-6 and has a time-depended effect on some haemostatic factors. | en |
| heal.journalName | Diabetes & Metabolism | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Kiortsis-2005-The effects of orlis.pdf | 89.62 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
